ACON
Aclarion, Inc.
There isn't enough reported data to score ACON yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ACON Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Unavailable | |
| Unavailable |
ACON's revenue is currently strong, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ACON PE Valuation
ACON has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ACON Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ACON's losses to shrink, with revenue growing.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ACON Earnings Per Share
ACON and HIMS do not have enough comparable growth data to identify a winner.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ACON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $33.7K | +78% |
| Q2 2026 | $25.2K | +30% |
| Q1 2026 | $21.1K | +11% |
| Q4 2025 | $18.5K | +81% |
| Q3 2025 | $18.9K | +31% |
| Q2 2025 | $19.3K | +76% |
| Q1 2025 | $19K | +88% |
| Q4 2024 | $10.2K | -26% |
ACON's revenue has grown year over year for seven quarters in a row: $33,733 last quarter, up 78% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -8165% | +1502 points |
| Q2 2026 | -11503% | -2515 points |
| Q1 2026 | -14129% | -6273 points |
| Q4 2025 | -10785% | +6868 points |
| Q3 2025 | -9666% | -671 points |
| Q2 2025 | -8989% | +1362 points |
| Q1 2025 | -7856% | +4753 points |
| Q4 2024 | -17653% | -9489 points |
ACON's operating margin was −8165% last quarter, up 1501 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ACON on profitability, with a higher operating margin.
ACON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2M | -$851K |
| Q1 2026 | -$2.6M | -$131.1K |
| Q3 2025 | -$1.2M | -$112K |
| Q1 2025 | -$2.5M | -$272.2K |
| Q3 2024 | -$1.1M | -$103.1K |
| Q2 2024 | -$1.1M | -$107K |
| Q1 2024 | -$2.2M | -$1.2M |
| Q4 2023 | -$733.8K | +$401.3K |
ACON has the stronger cash trend. Its trailing FCF is down 43% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ACON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +316K shares |
| 1 year | +377% | +2.2M shares |
ACON has 3M diluted shares, up 377% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ACON on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ACON Net Leverage
ACON's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ACON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 6.9 | Oversold |
ACON's weekly RSI is 30 (neutral) and its Stochastic is 7 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ACON PE vs Healthcare Sector
ACON has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ACON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.04 | 22% below |
| 20 week MA | $2.34 | 32% below |
| 50 week MA | $3.15 | 50% below |
| 100 week MA | $26.9 | 94% below |
| 200 week MA | $22,066.9 | 100% below |
ACON is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ACON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $393,638.4 | $69,465.6 | -82% |
| 2023 | $69,465.6 | $28,944.0 | -58% |
| 2024 | $28,944.0 | $128.1 | -100% |
| 2025 | $128.1 | $5.39 | -96% |
| 2026 YTD | $5.39 | $1.59 | -71% |
ACON has finished every year since 2022 lower, and it's down 71% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ACON on returns for 2026, with the stronger performance.